BioXcel Therapeutics
BTAI
BTAI
96 hedge funds and large institutions have $325M invested in BioXcel Therapeutics in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
11% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 27
0.75% more ownership
Funds ownership: 3% → 3.75% (+0.75%)
Holders
96
Holding in Top 10
–
Calls
$5.79M
Puts
$3.67M
Top Buyers
| 1 | +$26M | |
| 2 | +$24.9M | |
| 3 | +$22.5M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$4.19M |
| 5 |
Two Sigma Investments
New York
|
+$4.07M |
Top Sellers
| 1 | -$6.56M | |
| 2 | -$6.49M | |
| 3 | -$2.67M | |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.19M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.18M |